• Korean Journal of Head & Neck Oncology
• /
• v.17 no.2
• /
• pp.179-184
• /
• 2001

Objective: The role of chemotherapy in locally advanced head and neck cancer has been established in nasopharynx and larynx as definitive therapy and organ preserving therapy, respectively. Oral cavity cancers are relatively uncommon and local recurrence is the main cause of treatment failure. We planned this retrospective study to evaluate the role of neoadjuvant chemotherapy in locally advanced oral cavity cancer patients. Materials and Methods: From 1988 March to 2001 February, locally advanced, previously untreated oral cavity cancer patients who received neoadjuvant chemotherapy were examined. Chemotherapy had been done in the following patients: Histologically proven squamous cell or poorly differentiated carcinoma, stage 3 or 4, and performance state 0-2 patients. Chemotherapy regimen consisted of cisplatin and infusional 5-fluorouracil. Response was evaluated after 2 cycles and in case of no response, definitive local therapy was done; otherwise 3 cycles was done before local treatment. Results: 48 patients were treated and 47 patients were evaluable for responses. Complete response rate was 6.4%(3/47) and partial response 80.0%(38/47), scoring overall response rate of 87.2%. Median time to progression was 27.0 months (95% CI : 0-58months) and overall 5 year survival was 54.8%. 5-year disease-free survival in the patients in remission after local treatment was 51.9%. In multivariate analysis, contributing factor to the survival were response to neoadjuvant chemotherapy and local treatment modalities. Extensive surgery was done in 10 patients and 25 patents (52.1%) was followed up with preserved function. With median follow-up of 57.0 months, 19 recurrences were detected, most of which were local or regional type. Conclusion: Neoadjuvant chemotherapy followed by local treatment in oral cavity cancer showed high response rate and was thought to be effective therapeutic approach especially in view of organ preservation.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.1
• /
• pp.413-417
• /
• 2013

Purpose: This phase II study was undertaken to determine the efficacy and safety of Loubo$^{(R)}$ (Lobaplatin) in combination with pemetrexed in treating patients with metastatic breast cancer who failed to respond to anthracycline or taxanes. Patients and Methods: Metastatic breast cancer cases who had previously received an anthracycline and a taxane in either adjuvant or metastatic settings, were enrolled. All patients were recruited from Jiangsu Cancer Hospital and Research Institute, and were treated with Loubo$^{(R)}$ (Lobaplatin) 35 $mg/m^2$ (intravenous; on day 1) and pemetrexed 500 $mg/m^2$ (intravenous; on day 1) every 21 days. Efficacy and side effects were evaluated after at least two cycles of chemotherapy. Results: All eligible 19 patients completed at least 2 cycles of chemotherapy with pemetrexed and lobaplatin, and were evaluable. Overall, 3 (15.8%) patients achieved partial response, 11 (57.9%) stable disease, 5 (26.3%) progression of disease, with no complete remission. Response rate was 15.8%, disease control rate was 42.1%. The median survival time was 10.3 months. Neutrophil suppression occurred in 36.8% of patients who had grade 2 toxicity, and 26.3% had grade 3, 26.4% had grade 4. Thrombocytopenia was encountered as follows: 21.1% grade 2, 15.8% grade 3 and 5.5% grade 4. Incidences of anemia were 10.5% in grade 2, 5.3% grade 3 and 0% grade 4. Only 5.3% of patients required packed red blood cell transfusion. Grade 3 digestive tract toxicity occurred in 5.5% of patients. Other toxicities included elevated transaminase,oral mucositis and skin rashes. Conclusions: The regimen of lobaplatin and pemetrexed is modestly active in metastatic breast cancer patients who failed anthracycline or taxanes, and the toxicity profile suggesting that the doses of chemotherapy should be further modified.

• Journal of the Korean Crystal Growth and Crystal Technology
• /
• v.10 no.3
• /
• pp.219-225
• /
• 2000

The spinel structured $LiMn_2O_4$was obtained by two consecutive heat treatment on xerogel; the first heat treatment was at $150^{\circ}C$ and the second at $350^{\circ}C$ was obtained by sol-gel process using an aqueous solution of lithium hydroxide and manganese acetate. The synthesized $LiMn_2O_4$ by the sol-gel process showed a discharge capacity of 88~56 mAh/g after 15 cycles in Li/lM $LiClO_4$(in PC)/$LiMn_2O_4$at a current density of 0.25 mA/$\textrm{cm}^2$ and the voltage ranged 3.5 V to 4.3 V. For the second heat treatment above $350^{\circ}C$, $Mn_2O_3$was formed as a by-product during the synthesis of $LiMn_2O_4$. The heat treatment at $500^{\circ}C$, for example, showed a lower discharge capacity 81~47 mAh/g, after the 15 charge/discharge cycles. The lower capacity was due to the increment of $Mn^{3+}$ ion and this phenomenon was in agreement with the Jahn-Teller distortion.

• Asian Pacific Journal of Cancer Prevention
• /
• v.14 no.5
• /
• pp.2703-2706
• /
• 2013

Purpose: This study was to determine the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic gastric cancer who failed to respond to first and (or) second line chemotherapy. Patients and Methods: Metastatic gastric cancer patients who failed first and (or) second line chemotherapy, were enrolled. All patients were recruited from Jiangsu Cancer Hospital & Research Institute, and were treated with pemetrexed $500mg/m2$ (intravenous; on day 1), and a platinum (or irinotecan) every 3 weeks until disease progression, or intolerable toxicity. Evaluation on efficacy was conducted after two cycles of chemotherapy using the Response Evaluation Criteria for Solid Tumors. Toxicity was recorded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Results: From Jun 2011 to May 2013, 23 patients were enrolled. All eligible 23 patients completed at least 2 cycles of chemotherapy with pemetrexed based chemotherapy, and were evaluable. Their median age was 55 years (range 40 to 78 years). Seventeen patients were male and 6 female. Three patients (13%) achieved partial response, five patients (22%) stable, 15 patients (65%) with disease progression, and none with complete response. Grade 2 neutrophil suppression occurred in 4.3%, grade 3 in 13% of patients, and no grade 4 was reported. Thrombocytopenia was encountered as follows: 4.3% grade 2, 4.3% grade 3 and 4.3% grade 4. Incidence of anemia was 34.8% in grade 2, 8.7% grade 3 and 0% grade 4. Only 4.3% of patients required packed red blood cell infusion. Elevated transaminase were 4.3% in grade 2 and 0% in grade 3 or 4. Other toxicity included oral mucositis. Conclusions: Pemetrexed based chemotherapy is mildly effective in treating patients with metastatic gastric cancer with tolerable toxicity.

• Journal of the Korean Applied Science and Technology
• /
• v.30 no.2
• /
• pp.362-370
• /
• 2013

The coconut shell based activated carbon was applied for EDLC (electric double layer capacitor) electrode with the post treatments. The electrochemical properties were evaluated with a coin cell using the activated carbon as electrode. The initial gravimetric and volumetric capacitance of the coconut shell based activated carbon electrode s were 66 F/g and 39 F/cc, and these values decreased to 54 F/g and 32 F/cc after 100 cycles, respectively showing 82% of charge-discharge efficiency. The properties of CV graph with the commercial activated carbon electrodes showed the serious polarization as the result of additional reaction between electrolyte and impurities of the electrode materials. In order to remove impurities efficiently, the commercial activated carbon was treated by alkali and acid solutions consecutively, and then heat treated to control the pore size distribution and the content of surface functional groups. The surface functional groups decreased with the increased heat temperature and the specific capacitance increased with the decreased surface functional groups. The initial capacitance of coconut shell based activated carbon elec trode which was treated with NaOH and HNO3, and then heat treated at $800^{\circ}C$ was 44 F/cc, and the value turned out to be 42 F/cc after 100 cycles, showing over 95% of charge-discharge efficiency.

• Journal of Food Hygiene and Safety
• /
• v.12 no.1
• /
• pp.9-14
• /
• 1997

Vibrio mimicus is a closely related species with V. cholerae, and has been reported to be associated with gastrointestinal infections. Although extraintestinal infections of these vibrios have also been reported in Japan and Southeast Asia. But little research papers on V. mimicus was reported in Korea. Therefore, we tried to isolate V. mimicus from the environmental sea water from April to July in Pusan, Korea. Among the isolated strains, we selected the strongest hemolytic strain and then named V. mimicus SM-9. In this paper, we checked the antibiotic susceptibility and psychrotrophic characteristics of the isolated strain. Hemolytic activity of the hemolysin produced by the isolated strain was also measured. V. mimicus was not detected from the sea water samples in April and May, but its detection rate was relatively high in June and July in Pusan, Korea. The bacteriological characteristics of V. mimicus SM-9 were Gram-negative rods, motile, oxidase positive, Voges-Proskauer negative and sucrose negative. In 23 kinds of antibiotics susceptibility test, V. mimicus SM-9 showed susceptibility to the most of antibiotics submitted while it was resistive against lincomycin, oxacillin, rifampin and vancomycin. Hemolytic activity of the hemolysin produced by V. mimicus SM-9 was highest in stationary phase of the growth curve in BHI broth at 37$^{\circ}C$ and its activity was reached 18 HU per $m\ell$ of culture supernatant. For checking the psychrotrophic property of V. mimicus SM-9, the decreasing rate of the strain in phosphate buffer solution and yellowtail flesh homogenate was examined during the storage at 4, 0, -4 and -2$0^{\circ}C$. The decreasing rates of the selected strain stored in phosphate buffer solution were greater than those in fish homogenate. Decreasing rates of V. mimicus SM-9 stored in phosphate buffer solution were not significantly different by the storage temperatures. The viable cell counts of the strain were decreased as 5 log cycles after 120 hours at all the tested temperatures. While decreasing numbers of the strain in fish homogenates were 2*4 log cycles after 120 hours. The decreasing pattern of the strain numbers were very slow after 200 hours at all the stored temperatures.

• Journal of Food Hygiene and Safety
• /
• v.13 no.2
• /
• pp.99-105
• /
• 1998

Pectin hydrolysate prepared from citrus pectin by enzymatic hydrolysis has antimicrobial activity. The antimicrobial activity was increased by its hydrolyzing rate and it was rapidly increased after 70% hydrolysis of the pectin. The antibacterial activity of pectin hydrolysate against Escherichia coli ATCC 11229 was the strongest at pH 4.9~5.5, but it diminished slightly at neutral pH values. The antibacterial activity of pectin hydrolysate was stronger than those of against molds and yeasts. The growth of bacteria submitted to this test except lactics was completely inhibited for 48 hrs at $35^{\circ}C$ by adding 2.0~3.0% pectin hydrolysate. While the growth of Lactococcus lactis ATCC 19435 and Lactobacillus bulgaricus and Penicillium funiculosum ATCC 11797 were reached about 60~70% compared with those of the controls in the same condition. But there was no significant effect on the growth of the yeasts. The antibacterial effect of pectin hydrolysate was significantly stimulated by addition of glycine, ethanol, sodium ascorbate, sodium chloride and sodium acetate. The shelf life of Kimchi containing 1.0% pectin hydrolysate was prolonged above 15 days at $4^{\circ}C$ than that of its control. In case of whitish bean jam viable cell counts were inhibited about 2 log cycles by 10 days at $25^{\circ}C$. According to these results, author can sincerely suggest that pectin hydrolysate will be used as a natural food preservative for inhibition of common bacterial growth without inhibition of lactics and yeasts.

• Applied Chemistry for Engineering
• /
• v.10 no.8
• /
• pp.1192-1199
• /
• 1999

The morphology changes of cadmium hydroxide into ${\gamma}$ phase by eletrolytes were carried out to improve the high rate charge and discharge efficiency of pasted cadmium electrodes. KOH solutions with different concentrations of NaOH were used as eletrolytes. It was found that the utilization of active material of cadmium electrode was the best in an electrolyte with 1.82 M NaOH. The amount of ${\gamma}-Cd(OH)_2$ increased in proportion to the concentration of NaOH. The surface area measurement showed that an active material which contained mainly ${\gamma}-Cd(OH)_2$ had a higher specific surface area than an active material of ${\beta}-Cd(OH)_2$. In a sealed cell, the discharge capacity was improved at high rate charge and discharge (1.0 C, 2.0 C) by using an electrolyte with NaOH. Furthermore, these improved performances were maintained up to 500 cycles at 1.0 C rate charge and discharge cycles.

• Korean Chemical Engineering Research
• /
• v.61 no.1
• /
• pp.58-61
• /
• 2023

The activation process is essential for PEMFC to improve initial performance. The most commonly used activation method is a voltage change (load change) method, which may accompany degradation of the electrode catalyst if excessively performed. In many activation processes, the voltage change range is activated in a wide range from 0.4 V to OCV, and research is needed to reduce the voltage change range in order to prevent electrode catalyst degradation and shorten the activation time. Therefore, in this study, when the activation voltage range was 0.4~0.6 V, 0.4~0.8 V, and 0.4~OCV, we tried to research and develop an effective activation method by analyzing the performance and characteristics of the electrode and polymer membrane. The performance improvement was the lowest in the activation with a wide voltage range from 0.4 V to the highest OCV, and the performance decreased by 10% when activated for 56 cycles. The 0.4~0.6 V activation cycle showed the highest performance improvement up to 20% and the smallest decrease in performance due to overactivation, indicating that it is optimal method.

• Radiation Oncology Journal
• /
• v.26 no.3
• /
• pp.160-165
• /
• 2008

Purpose: In cases of locally advanced non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy(CCRT) is the leading therapeutic modality. However, much controversy exists about the chemotherapeutic regimens and radiation methods. Materials and Methods: During concurrent chemoradiotherapy, three or four cycles of gemcitabine ($500\;mg/m^2$) and cisplatin ($30\;mg/m^2$) were administered every two weeks while 50.4 Gy of irradiation was administered in 28 fractions (once/day, 5 treatment days/week) to the tumor site, mediastinum, and the involved lymph node region. In addition, a booster irradiation dose of 18 Gy in 10 fractions was administered to the primary tumor site unless the disease progressed. Two or three cycles of consolidation chemotherapy were performed with gemcitabine ($1,200\;mg/m^2$, $1^{st}$ and 8th day) and cisplatin ($60\;mg/m^2$) every three weeks. Results: A total of 29 patients were evaluable for modality response. Response and treatment toxicities were assessed after concurrent chemoradiotherapy and consolidation chemotherapy, respectively. One patient (4%) achieved a complete response; whereas 20 patients (69%) achieved a partial response after concurrent chemoradiotherapy. Following the consolidation chemotherapy, three patients (10.3%) achieved complete responses and 21 patients (72.4%) achieved partial responses. The median follow-up period was 20 months (range $3{\sim}39$ months) and the median survival time was 16 months (95% CI; $2.4{\sim}39.2$ months). The survival rates in one, two, and three years after the completion of treatment were 62.7%, 43.9%, and 20%, respectively. Complications associated to this treatment modality included grade 3 or 4 esophagitis, which occurred in 15 patients (51.7%). In addition, an incidence of 24% for grade 3 and 14% for grade 4 neutropenia. Lastly, grade 2 radiation pneumonitis occurred in 6 patients (22%). Conclusion: The response rate and survival time of concurrent chemoradiotherapy with biweekly gemcitabine ($500\;mg/m^2$) and cisplatin ($30\;mg/m^2$) were encouraging in patients with locally advanced NSCLC. However, treatment related toxicities were significant, indicating that further modification of therapy seems to be warranted.